This allows for the selection of amyloid-positive, tau-negative populations to show disease modification in early disease through tau-targeting therapeutics, i.e. preventing occurrence of tau pathology and progression to AD in high-risk populations. The gene discussed is MAPT; the disease is Alzheimer disease.